| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.1 | 0.3 |
| Gross profit | 0.9 | 0.2 |
| Net income | -3.6 | -2.9 |
| EPS (diluted, $ a share) | $-0.08 | $-0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +300.8% |
|---|---|
| Gross margin | 82.4% |
| Operating margin | -303.6% |
10-Q filed with the SEC, NASDAQ: RNXT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
RenovoRx, Inc.: key numbers
- Share price
- $0.9549Close, Nov 16
- Market cap
- $46.1M
- Shares outstanding
- 48.25MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from RenovoRx, Inc.
All →RenovoRx Executive Chairman and CMO Ramtin Agah Buys $46.5K of Stock
Ramtin Agah, Executive Chairman and CMO, bought 50,000 shares of RenovoRx, Inc. at $0.9297 a share, worth $46.5K in total on Nov 16, 2026. Shares held after the trade: 848,460 (+6.3%).
- Value
- $46.5K
- Shares
- 50,000
- Price
- $0.9297
- Role
- Executive Chairman and CMO
- Holding change
- +6.3%
- Trade date
- Nov 16, 2026
RenovoRx Financial Results
RenovoRx reported record third-quarter 2026 revenue exceeding $1 million, representing a four-fold increase year-over-year. The company expanded its active commercial cancer center customer base to 26 and reaffirmed its full-year 2026 revenue guidance of $3.75 million to $4.25 million.
- Term
- Q3 2026
“We generated record results in the third quarter as revenue exceeded the million-dollar threshold and we continued to deliver on all three of our core priorities.”
Shaun Bagai, Chief Executive Officer of RenovoRx
“Looking ahead, given the strong momentum, we continue to expect full-year 2026 revenue for RenovoCath in the range of $3.75 million to $4.25 million, which would more than triple 2025 revenue at the midpoint.”
Shaun Bagai, Chief Executive Officer of RenovoRx